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Only 30 or 40 years ago, rheumatic fever was a com-
mon topic in the Journal. A PubMed 
search for articles on rheumatic 
fever published between 1967 and 
1976 returned 55 New England Jour-
nal of Medicine articles — fewer 
than for endocarditis (77) but 
more than for stroke and syphi-
lis (24 entries each). A similar 
PubMed search for the decade 
1997 through 2006 yielded just 
eight entries for rheumatic fever. 
This trend holds for all Medline-
indexed journals: an average of 
516 articles on rheumatic fever per 
year from 1967 through 1976, 
but only 172 per year from 1997 
through 2006. Most observers 
would probably consider this de-
crease to be a reasonable reflec-
tion of the waning incidence of 
the disease. After all, in the mid-
20th century, children with rheu-
matic fever occupied many of the 
beds in pediatric wards in indus-
trialized countries — indeed, en-
tire hospitals were dedicated to 
the treatment of, and rehabilita-
tion from, rheumatic fever. But 
in the latter half of the 20th 
century, rheumatic fever receded 
as an important health problem 
in almost all wealthy countries. 
Today, most physicians in these 
countries are unlikely ever to see 
a case of acute rheumatic fever, 
and their experience with rheu-
matic heart disease will be lim-
ited to heart-valve lesions in older 
patients who had rheumatic fever 
in their youth.
The reality, however, is that the 
decrease in publications reflects 
only the waning burden of disease 
among the less than 20% of the 
world’s population living in high-
income countries. For everyone 
else, rheumatic fever and rheumat-
ic heart disease are bigger prob-
lems than ever. It was estimated 
recently that worldwide 15.6 mil-
lion people have rheumatic heart 
disease and that there are 470,000 
new cases of rheumatic fever and 
233,000 deaths attributable to 
rheumatic fever or rheumatic heart 
disease each year.1 These are con-
servative estimates — the actual 
figures are likely to be substan-
tially higher. Almost all these cas-
es and deaths occur in developing 
countries.
How did rheumatic fever be-
come rare in wealthy countries? 
Medical science can take some of 
the credit, thanks largely to the 
use of penicillin for primary pre-
vention, but most of the reduction 
is attributable to improved living 
conditions, which have resulted in 
less overcrowding and better hy-
giene, with consequent reductions 
in transmission of group A strep-
tococci. In other words, rheumatic 
fever is a disease of poverty. That 
it is in many ways the epitome of 
diseases of poverty and social in-
justice is exemplified by the situ-
ations in Australia and New Zea-
land. In these countries, which 
boast living standards that are 
among the best in the world, 
there are indigenous populations, 
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an impressive list of unexpected 
associations between genes or 
chromosomal regions and a broad 
range of diseases. There have 
been few, if any, similar bursts 
of discovery in the history of med-
ical research. Relatively conven-
tional statistical techniques are 
adequate for the analysis and in-
terpretation of these initial stud-
ies. But as we delve further into 
the genome in the search for net-
works of interacting gene vari-
ants and interactions between 
these networks and environmen-
tal factors,5 much more sophis-
ticated methods of statistical 
analysis are likely to be required.
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stitute’s Cancer Genetic Markers of Sus-
ceptibility project. Dr. Kraft is an assistant 
professor of epidemiology and biostatis-
tics at the Harvard School of Public Health, 
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many of whose members live in 
poverty, with documented rates 
of rheumatic fever and rheumat-
ic heart disease that are among 
the highest in the world.1 Among 
aboriginal people of northern Aus-
tralia, for example, acute rheu-
matic fever develops in 0.2 to 
0.5% of school-age children each 
year, and more than 2% of peo-
ple of all ages have rheumatic 
heart disease.
An unfortunate consequence 
of the decline in rheumatic fever 
in industrialized countries has 
been a parallel reduction in re-
lated research. Indeed, although 
our understanding of the patho-
genesis of this mysterious dis-
ease has improved somewhat, the 
only advances that have substan-
tially altered the management or 
prevention of rheumatic fever dur-
ing the past 40 or 50 years have 
occurred in the medical and sur-
gical treatment of severe rheu-
matic heart disease — treatment 
that is largely palliative and nei-
ther accessible nor affordable to 
the majority of affected patients. 
The mainstays of the control of 
rheumatic fever remain treatment 
of group A streptococcal pharyn-
gitis with penicillin (primary pro-
phylaxis) and administration of 
penicillin G benzathine injections 
every 3 to 4 weeks for many years 
in people with a history of rheu-
matic fever to prevent recurrent 
episodes (secondary prophylaxis). 
Both strategies are based on find-
ings from seminal studies in the 
United States published in the 
1950s.2,3
The available and potential con-
trol measures for rheumatic fe-
ver and rheumatic heart disease 
are summarized in the diagram. 
Of these, only one — secondary 
prophylaxis — has been proved 
to be cost-effective and practical 
even in the poorest countries. For 
more than 20 years, the World 
Health Organization has recom-
mended secondary prophylaxis, 
most effectively delivered within 
a coordinated program using a 
registry of patients, as the first 
priority for the control of rheu-
matic heart disease.4 Yet most 
developing countries still do not 
have effective secondary-prophy-
laxis programs.
How to ensure that secondary 
prophylaxis is delivered to those 
who need it is one of several crit-
ical questions related to the imple-
mentation of current knowledge 
about the control of rheumatic fe-
ver and rheumatic heart disease. 
Other relevant questions include 
how to identify people with mild 
rheumatic heart disease so that 
they may be offered secondary 
prophylaxis earlier, whether pri-
mary prophylaxis can be a practi-
cal and cost-effective public health 
measure in developing countries, 
and how to ensure that limited 
health care funds are spent most 
effectively — which may entail 
shifting some funding from the 
provision of expensive cardiac sur-
gery for severe rheumatic heart 
disease to the development of ro-
bust secondary-prophylaxis pro-
grams.
Other key issues revolve around 
the need to develop new approach-
es to primary prevention, partic-
ularly a vaccine that protects 
against rheumatic fever. A num-
ber of vaccines are in development, 
and a safe and effective vaccine 
may well be available within one 
or two decades. However, experi-
ence with other relatively recent 
vaccines, including conjugate 
pneumococcal and Haemophilus in-
f luenzae type B vaccines, suggests 
that there may be many barriers 
to the funding, acceptance, and 
use of new vaccines in the places 
that need them most. Potential 
alternative strategies, including 
controlling streptococcal skin in-
fections, are intriguing but of un-
proven benefit.5
How will these issues be ad-
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dressed? Although some basic re-
search on pathogenesis and the 
development of early-stage vac-
cine candidates can take place in 
laboratories anywhere in the 
world, the clinical, epidemiolog-
ic, and public health studies re-
quire access to populations with 
high rates of disease. In recent 
years, many such studies have been 
conducted in Australia, New Zea-
land, and the Rocky Mountain 
region of the United States. But 
applied research of relevance to 
developing countries should take 
place in developing countries — 
a proposition that presents many 
obvious challenges. Even if bar-
riers caused by poor education, 
the absence of a skilled work-
force, limited finances, inadequate 
technology, and remoteness of the 
populations that are at the high-
est risk of disease can be over-
come, the burden of rheumatic 
fever and rheumatic heart disease 
is often either unappreciated or 
dwarfed by epidemics of human 
immunodeficiency virus, malaria, 
tuberculosis, and pneumonia.
Marijon and colleagues are to 
be applauded for the results of the 
study reported in this issue of 
the Journal (pages 470–476). The 
study represents a partnership 
among researchers in Mozam-
bique, Cambodia, France, and 
Australia. It tackles an important 
practical issue: whether and how 
to conduct screening for rheumat-
ic heart disease among school-age 
children in developing countries. 
Also, it presents a compelling ar-
gument for the use of echocar-
diographic screening (see image). 
The counterargument is that the 
use of such expensive technology 
is neither feasible nor affordable 
in the countries with the highest 
disease burden. Yet if clinical di-
agnosis had been relied on, ap-
proximately 90% of echocardio-
graphically detected cases would 
have been missed. It is not ac-
ceptable to leave these cases un-
diagnosed and these children at 
risk for recurrence of rheumatic 
fever simply because echocardio-
graphic screening is seen as an 
inappropriate use of modern tech-
nology in developing countries. 
Instead, further research is need-
ed to define models of echocar-
diographic screening that are 
practical, affordable, and widely 
applicable.
Marijon et al. found that 2 to 
3% of school-age children in 
Cambodia and Mozambique have 
rheumatic heart disease, almost 
all of it previously undiagnosed. 
We know that this represents the 
tip of the iceberg: cases in chil-
dren 5 to 14 years of age are like-
ly to represent only 15 to 20% of 
all cases in the population.1 These 
data confirm that rheumatic fe-
ver and rheumatic heart disease 
are of sufficient importance to 
warrant the urgent attention of 
the international public health 
and research communities.
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Still Image from a Two-Dimensional Echocardiogram in a Patient with Moderate 
Mitral Regurgitation Due to Rheumatic Heart Disease.
An apical four-chamber view is shown, with color Doppler imaging illustrating a 
regurgitant-flow signal that extends along the lateral wall of the left atrium. The blue-
and-yellow mosaic pattern indicates the regurgitant jet (arrow). (Courtesy of Dr. 
Andrew Steer, University of Melbourne.)
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